Predicting the Price of Drugs Years Before Launch

OKRAOKRA, a Cambridge-based provider of Artificial Intelligence (AI) analytics for Life Sciences, has developed a new AI system to accurately predict the (a) price and (b) 'benefit outcome' of new drug molecules several years before launch. OKRA's system is the first of its kind and uses AI to deliver detailed evidence and reassurance to pharma professionals to aid the submission process, opening doors for more effective drugs to reach the market faster.

OKRA combined its AI expertise with top 5 pharma industry domain knowledge to create ValueScope, a game-changing AI system for pricing and market access executives. ValueScope enables market access and pricing teams to perform scenario analysis of 'payer negotiations', an essential part of bringing a molecule to market. ValueScope sits on top of an AI engine that is the most robust of its kind, having learnt from millions of data points including tens of thousands of clinical trial results, historic drug submissions, the latest pricing data, and HTA reports (from IQWiG and G-BA).

OKRA has validated ValueScope in Germany, achieving >90% accuracy when predicting the benefit outcome and negotiated price of Phase III treatments.

The benefits of this product are clear. The system enables market access and commercial teams to perform assessments of early drug candidates faster and more efficiently than before, without the need for extensive pricing research and repetitive data crunching. Scenarios can be built more reliably and decisions can be taken quicker and with more confidence. OKRA’s clients will be able to spend more time building realistic Target Value Propositions and delivering evidence, without wasting time on debates about whether the pricing and reimbursement will eventually work when all the clinical and economic data generation has ended. Thanks to ValueScope, pharmaceutical experts can focus on value for patients and society with the reassurance that an AI system has reliably informed them about what constitutes a fair price based on previous decisions.

"ValueScope provides intelligence that pharma executives require when critical decisions about future investments and patient access are made," said Dr Loubna Bouarfa, CEO and Founder of OKRA. "We use data to bring clarity and transparency to the table. We provide control and confidence to access experts in order to generate competitive advantage with authenticity and trust. Let’s deliver more medicines to patients with evidence that supports their real benefits and price."

For further information and to register, please visit:
https://okra.ai

About OKRA's technology

OKRA's products for market access, commercial and medical executives are built on the most sophisticated AI. Coupled with OKRA's Hybrid Explainability Engine and 'glass box' promise, the company empowers users by providing full reasoning behind every prediction.

About OKRA

At OKRA we are fostering a new generation of Artificial Intelligence (AI) solutions that support the healthcare ecosystem. Our solutions are implemented by top pharma companies throughout the product pipeline to empower employees in decision making around complex problems.

OKRA's AI solutions are translating large clinical, scientific and commercial data sets into actionable insights that employees in life science companies can easily query at their desks or whilst on the move.

We believe that for AI to truly empower people, the insights presented must be explainable and instil confidence when driving action. Our suite of products have been built in partnership with top life science companies, with a focus on empowering the people to take action.

Most Popular Now

Accelerating Data Solutions to Save LIVE…

The consortium of COVID-X announces the launch of the ​1st Open Call ​framed in a ​2-year initiative that will invest ​4 million € to fast-track to market 30+ European data...

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...

Bayer Transforms Pharma Business through…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are...